

November Program

TUESDAY, NOVEMBER 18, 2003

SPEAKER: **Lee E. Babiss, Ph.D.**
Vice President, Preclinical Research and Development
Hoffmann-La Roche Inc.

TOPIC: The Impact of Pharmacogenomics on the Pharma and Diagnostic Business Models

At this program, Dr. Lee Babiss, Vice President of Preclinical Research and Development, Hoffmann-La Roche, will share his expertise in the area of pharmacogenomics. His discussion will include:

- Biomarkers and their applications to drug discovery
- Synergies between pharma and diagnostics
- Changing medical practice through the use of biomarkers

Dr. Babiss' responsibilities at Hoffmann-La Roche currently include: developing and directing the research strategy for the Nutley, New Jersey site; and serving as members of the Pharma Leadership Board chaired by the company's President and CEO, Pat Zenner, the International Research Executives; and the Global Genetics Board.

Previously, Dr. Babiss was Vice President of Biological Sciences and Genetics at Glaxo Wellcome. During his tenure with Glaxo, Dr. Babiss' positions included Group Leader in Cell Biology, where he focused on the development of antisense technology and cancer therapeutics, and Head of the Department of Molecular Cell Biology, where he played a key role developing and implementing the corporate Cell Cycle Program. Following the merger of Glaxo Inc. with Burroughs Wellcome in 1994, Dr. Babiss was named a member of the U.S. Research Senior Management Team, which was charged with formulating the company's U.S. research strategy. In partnership with scientific leaders throughout the organization, Dr. Babiss also worked to create the Glaxo Wellcome Corporate Genetic Strategy, which led to the creation of the company's Genetics Division.